Giotrif 40 mg, 28 tablets (Afatinib 40 mg per tablet) by Boehringer Ingelheim.
Indications: EGFR mutation-positive locally advanced or metastatic NSCLC; squamous NSCLC progressing after platinum chemotherapy.
Administration: Oral: 40 mg once daily, at least 1 hour before or 3 hours after food.
Storage: Store below 25–30 °C in the original package. Keep out of the sight and reach of children.
Prescription-only medicine (POM). Supplied against a valid prescription / to licensed healthcare professionals only.
| Manufacturer | Boehringer Ingelheim |
| Active ingredient | Afatinib 40 mg per tablet — irreversible ErbB family blocker. |
| Strength & pack | 28 film-coated tablets. |
| Form | Film-coated tablets |
| Storage | Store below 25–30 °C in the original package. Keep out of the sight and reach of children. |
| Regulatory status | Prescription-only medicine (POM). Supplied against a valid prescription / to licensed healthcare professionals only. |